| Stereochemistry | ABSOLUTE |
| Molecular Formula | C10H12N4O5 |
| Molecular Weight | 268.2261 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2C=NC3=C2N=CNC3=O
InChI
InChIKey=UGQMRVRMYYASKQ-KQYNXXCUSA-N
InChI=1S/C10H12N4O5/c15-1-4-6(16)7(17)10(19-4)14-3-13-5-8(14)11-2-12-9(5)18/h2-4,6-7,10,15-17H,1H2,(H,11,12,18)/t4-,6-,7-,10-/m1/s1
| Molecular Formula | C10H12N4O5 |
| Molecular Weight | 268.2261 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Inosine is a naturally occurring nucleoside which serves as an intermediate in purine metabolism. The metabolism of purines in humans generates a potent antioxidant compound, uric acid, which is known to be a natural scavenger of both oxygen and nitrogen reactive species as well as having chelator properties. Inosine, as a precursor of uric acid, was shown to have neuroprotective effect in vitro and is being tested in phase III of clinical trials for the treatment of Parkinson disease. The treatment with inosine is belived to prevent or slow the disease.
CNS Activity
Approval Year
Doses
PubMed
Patents
Sample Use Guides
Capsules containing 500 mg of inosine should be taken orally up to two capsules three times per day (i.e., up to 3 g/day) for 24 months.
Route of Administration:
Oral
Showing 1 to 3 of 3 entries
|
|
ACTIVE MOIETY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
WEIGHT PERCENT
[<0.2] % (limits) peak value |
Showing 1 to 1 of 1 entries